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Introduction
The encapsulated basidiomycetous yeast, Cryptococcus 
neoformans is distributed world-wide mainly in asso-
ciation with bird excrement (Srikanta et al. 2014). The 
species is an opportunistic human pathogen and can 
cause serious disease primarily in immunocompromised 
individuals, i.e. HIV-positive patients, patients with organ 
transplants undergoing immunosuppressive therapy and 
cancer patients going through chemotherapy; making 
them vulnerable to fungal infection. The infection of 
immunocompetent hosts is rare. The disease caused by 
C. neoformans is called cryptococcosis. The infection 
starts with the inhalation of the airborne basidiospores 
or dried cells (Köhler et al. 2015). The spores germinate in 
the lungs, thereafter the cells disseminated by the blood 
stream can reach and colonize the central nervous system 
establishing meningoencephalitis. Cryptococcosis affects 
about 1 million people in the world - most of them are 
HIV-infected - and causes the death of more than 600 000 
patients per year (Warkentien and Crum-Cianfloan 2010). 
The majority  of the cases are registered in certain parts 
of Africa and Asia where the incidence of HIV-infection 
is higher (Sloan and Parris 2014). 
A combined antifungal therapy involving amphotericin 
B deoxycholate and flucytosine is recommended for the 
treatment of cryptococcal meningoencephalitis (Day et 
al. 2013). However, flucytosine is an unregistered drug in 
most parts of Asia and Africa and its cost is high because 
of the limited number of manufacturers and these factors 
make the administration of this drug near impossible 
(Loyse et al. 2013).
Many non-antifungal pharmaceuticals have an an-
tifungal side effect. Some of them can act alone while 
others can enhance the activity of antifungal agents when 
used together (Afeltra and Verwe 2003; Judd and Martin 
2010; Nyilasi et al. 2010). Among the non-antifungals, 
the activity of phenothiazines like trifluoperazine and 
chlorpromazine, have been studied in detail. However, the 
antifungal activity of amantadine and valproic acid were 
only recognised recently against opportunistic human 
pathogenic fungal species (Wood and Nugent 1985; Eilam 
et al. 1987; Homa et al. 2015; Chaillat et al. 2017). Aman-
tadine is an ion channel blocker used to treat Parkinson’s 
disease (Blanpied et al. 2005). The anti-epileptic drug, 
valproic acid inhibits the action of histone deacetylases 
(HDACs) and induces the degradation of HDAC2 (Göt-
tlicher 2004). The antipsychotic drugs chlorpromazine 
and trifluoperazine exert their antifungal activity via 
arresting the cell cycle and destroying the cell membrane 
integrity in the susceptible species (Eilam et al. 1987). All 
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these drugs can penetrate across the blood brain barrier 
and can act in the central nervous system. 
The aim of this study was to test the in vitro anti-
Cryptococcus activity of amantadine, chlorpromazine, 
trifluoperazine and valproic acid against five C. neo-
formans strains, and to evaluate their interaction with 
amphotericin B.
Materials and methods
Yeast strains and growth conditions
The C. neoformans strains used in the present study are 
listed in Table 1. The strains were cultivated on Yeast 
Peptone Dextrose medium (YPD, 0.5% yeast extract, 1% 
peptone, 1% dextrose, 2% agar) at 30 °C for 48 hours and 
were kept at 4 °C until use. 
The experiments were carried out with actively grow-
ing cells; therefore, a single colony was transferred to 
2 mL sterile YPD medium and incubated at 30 °C for 
overnight. Cells were then harvested by centrifugation at 
10000 rpm for 5 minutes in Heraeus Pico 17 centrifuge 
(Thermo Scientific, Waltham, MA, US) and washed twice 
with sterile distilled water, finally they were suspended 
in RPMI 1640 medium (Sigma-Aldrich, Germany).
Non-antifungal compounds
Amantadine hydrochloride, chlorpromazine hydrochlo-
ride, trifluoperazine hydrochloride, valproic acid sodium 
salt (Sigma-Aldrich, Germany) and amphotericin B (Ap-
pliChem, Darmstadt, Germany) were provided by the 
manufacturers as standard powder. The non-antifungal 
compounds were dissolved in 96% ethanol while ampho-
tericin B in dimethyl sulfoxide (DMSO) to prepare stock 
solutions (10 mg/mL and 1 mg/mL, respectively) which 
was stored at -20 °C until used. Further dilutions were 
performed in RPMI 1640 medium. 
Antifungal activity assays
Determination of Minimal Inhibitory Concentration (MIC)
The antifungal effect of the drugs was determined by broth 
micro-dilution assay in 96-well flat bottom microplate. 
Fifty µl serially twofold diluted compounds were added 
to 50 µl of standardized cell suspension (8 x 104 cell/mL 
in RPMI 1640 medium). The final concentration of the 
amphotericin B was ranged from 0.156 to 5.0 µg/mL, and 
those of amantadine, chlorpromazine, trifluoperazine and 
valproic acid from 7.81 to 500 µg/mL. The control samples 
contained 50 µl cell suspension and 50 µl RPMI 1640 
medium. Solvent control was used to check the effect of 
the ethanol and DMSO on the growth rate of the strains.
The plates were incubated at 30 °C for 48 h. At the end 
of the incubation, the optical density of the samples was 
detected at 620 nm in SPECTROstar Nano plate reader 
(BMG LabTech, Offenburg, Germany). The experiments 
were carried out at least three times always in triplicates. 
The MIC was defined as the concentration of the com-
pound caused total inhibition of cell growth.
Interaction between amphotericin B and the non-antifungal 
compounds
The in vitro interaction of the compounds and amphoteri-
cin B was determined by standard checkerboard titration 
method. The amphotericin B was tested in a concentration 
range from 0.156 to 2.5 µg/mL while the concentration 
ranges of all the other compounds varied from 7.81 to 
125 µg/mL. The cell concentration in each well was 4 x 
104 cell/mL. After the incubation for 48 h at 30 °C, the 
optical density of the cultures was detected at 620 nm 
Species Strain number
Cryptococcus neoformans IFM 5844
Cryptococcus neoformans IFO 410
Cryptococcus neoformans SZMC 26851
Cryptococcus neoformans SZMC 26852
Cryptococcus neoformans IFM 48637
Table 1. List of the tested strains
IFM: Culture Collection of the Research Centre for Pathogenic Fungi and 
Microbial Toxicoses, Chiba University, Chiba, Japan
IFO: Institute for Fermentation, Osaka, Japan
SZMC: Szeged Microbiological Collection
Species
Minimal inhibitory concentrations (µg/mL)
amphotericin B amantadine chlorpromazine trifluoperazine valproic acid
Cr. neoformans IFM 5844 0.625 >500 125 62.5 >500
Cr. neoformans IFO 410 0.625 >500 62.5 62.5 >500
Cr. neoformans SZMC 26851 0.625 >500 125 62.5 >500
Cr. neoformans SZMC 26852 0.625 >500 125 62.5 >500
Cr. neoformans IFM 48637 0.625 >500 125 62.5 >500
Table 2. Antifungal activity of the compounds
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in SPECTROstar Nano plate reader (BMG LabTech, Of-
fenburg, Germany). The MIC was determined for each 
compound alone and in combinations. The experiments 
were carried out at least three times always in triplicates.
Data analysis
For calculation of the inhibition rates, the absorbencies 
of the untreated control cultures were assumed to be 
100% growth in each case. Expected efficacy of each 
combination was determined by the Abbott formula: Ie = 
X + Y – (XY/100), where Ie is the expected percent inhibi-
tion for a given interaction, and X and Y are the percent 
growth inhibited by the compounds when used alone. The 
nature of interaction of these antifungal compounds was 
determined by the interaction ratios (IRs), which were 
computed as IR = Io/Ie (Io, observed percent inhibition). 
IRs between 0.5 and 1.5 represent additive interactions, 
ratios of >1.5 represent synergistic interaction, and ratios 
of <0.5 represent antagonistic interactions.
Results
Antifungal activity of the tested drugs
The antifungal activities are summarised in Table 2. 
All the examined strains were slightly susceptible to 
the drugs. Among the non-antifungal compounds, the 
MIC of trifluoperazine proved the lowest: 62.5 µg/mL. 
Chlorpromazine showed the same MIC (62.5 µg/mL) for 
C. neoformans IFO 410 strain, all the other strains were 
less susceptible, as the MIC was 125 µg/mL in that case. 
The MIC of amantadine and valproic acid could not be 
established as it was out of the applied concentration 
range.  The MIC of amphotericin B was 0.625 µg/mL 
for each strain.
Interaction between amphotericin B and the non-anti-
fungal compounds
Positive interactions were detected between the am-
photericin B and each compound. All the tested drugs 
augment the effectiveness of the amphotericin B against 
C. neoformans strains as additive and synergistic interac-
tions occurred between them (Table 3). Using C. neofor-
mans SZMC 26851 as susceptible strain synergism was 
detected combining amphotericin B either with valproic 
acid or trifluoperazine. Valproic acid and amphotericin 
B combination showed synergistic interaction against 
IFM 48637 strain too. All the other combinations dem-
onstrated additive interactions between amphotericin B 
and the drugs against the tested strains. 
Discussion
Cryptococcosis is a world-wide infectious disease asso-
ciated mainly with immunodeficient hosts. The disease 
most commonly manifests as cryptococcal meningitis. 
However, pulmonary and primary cutaneous cryptococ-
cosis also exist (Sloan and Parris 2014). As other invasive 
fungal infections, cryptococcosis is associated with high 
morbidity and mortality rate. Particularly the treatment 
of cryptococcal meningoencephalities affecting the cen-
tral nervous system is difficult because amphotericin B 
having significant role in the treatment penetrates poorly 
across the blood brain barrier due to its relatively high 
molecular weight (Nau et al. 2010). Additional problem 
is the low accessibility of the other recommended drug, 
flucytosine (Loyse et al. 2013). 
The in vitro broad-spectrum activity of non-anti-
fungal compounds against human pathogenic fungi 
was published earlier ( Judd and Martin 2009). Testing 
the activity of phenothiazines such as chlorpromazine 
and trifluoperazine against medically important yeasts 
such as C. neoformans proved that it is one of the most 
susceptible species (Eilam et al. 1987). Although, the 
anti-Cryptococcus activity of these compounds has been 
established earlier, their interaction with amphotericin 
B was not investigated. In this present study, the in vitro 
action of chlorpromazine, trifluoperazine, valproic acid 
and amantadine individually and in combination with 
amphotericin B were studied. The results showed that 
all the examined compounds possess antifungal activ-
Drugs
Strains
IFM 5844 IFO 410 SZMC 26851 SZMC 26852 IFM 48637
AMB +
amantadine 0.93 ADD 1.04 ADD 0.82 ADD 0.70 ADD 0.92 ADD
chlorpromazine 0.94 ADD 1.04 ADD 0.85 ADD 0.88 ADD 0.97 ADD
trifluoperazine 1.29 ADD 1.02 ADD 1.51 SYN 1.29 ADD 1.09 ADD
valproic acid 1.07 ADD 0.86 ADD 1.88 SYN 1.12 ADD 1.55 SYN
AMB: amphotericin B; ADD: additive interaction; SYN: synergistic interaction
Table 3. Interaction ratios between amphotericin B and amantadine, chlorpromazine, trifluoperazine and valproic acid after 48-h incubation at 30 °C
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ity as they slightly reduced the growth of C. neoformans 
strains when applied alone. Trifluoperazine was the most 
efficient drug as it had the lowest MIC against all the five 
strains involved in this study. The drugs and ampho-
tericin B established additive or synergistic interactions 
as in combination with amphotericin B they achieved 
more effective growth inhibition than being used alone. 
Amphotericin B in combination with the studied drugs 
attained more efficient growth reduction in lower con-
centrations than used alone.  
 The positive interaction between the drugs and am-
photericin B can be explained by the ability of amphoteri-
cin B to bind to the ergosterol and forming pores in the 
fungal cell membrane (Gallis et al. 1990). Non-antifungal 
agents could enter the cells via these pores and could exert 
their activity within the fungal cell. Amantadine, chlor-
promazine, trifluoperazine and valproic acid accumulates 
in the central nervous system and there is potential to 
apply them in combination with amphotericin B in the 
treatment of Cryptococcus-caused meningoencephalitis.
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